UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 2, 2015

 

PACIRA PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-35060

 

51-0619477

(State or other jurisdiction

 

(Commission

 

(IRS Employer

of incorporation)

 

File Number)

 

Identification No.)

 

5 Sylvan Way, Suite 300, Parsippany, New Jersey 07054

(Address of principal executive offices) (Zip Code)

 

(973) 254-3560

Registrant’s telephone number, including area code

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 5.07.         Submission of Matters to a Vote of Security Holders.

 

On June 2, 2015, Pacira Pharmaceuticals, Inc. (the “Company”) held its 2015 Annual Meeting of Stockholders at the Company’s corporate headquarters in Parsippany, New Jersey, at which the Company’s stockholders voted on, and approved, the following proposals:

 

Proposal No. 1 — Election of three Class I directors to hold office until the 2018 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified.

 

Nominee:

 

For

 

Withheld

 

Broker Non-
Votes

 

Laura Brege

 

25,148,577

 

2,703,160

 

5,270,606

 

Mark A. Kronenfeld

 

26,686,306

 

1,165,431

 

5,270,606

 

Dennis L. Winger

 

27,763,019

 

88,718

 

5,270,606

 

 

Proposal No. 2 —  Ratification of the appointment of CohnReznick LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2015.

 

For

 

Against

 

Abstain

 

33,054,850

 

41,601

 

25,892

 

 

Proposal No. 3 —  Advisory vote to approve the compensation of the Company’s named executive officers.

 

For

 

Against

 

Abstain

 

Broker Non-
Votes

 

27,579,771

 

214,828

 

57,138

 

5,270,606

 

 

2



 

Signatures

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

PACIRA PHARMACEUTICALS, INC.

 

 

Date: June 3, 2015

By:

/s/ James Scibetta

 

 

James Scibetta
Senior Vice President, Chief Financial Officer
and Head of Technical Operations

 

3